These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25317242)

  • 1. Diabetes treatment in patients with renal disease: Is the landscape clear enough?
    Ioannidis I
    World J Diabetes; 2014 Oct; 5(5):651-8. PubMed ID: 25317242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.
    Gallwitz B
    Ther Adv Endocrinol Metab; 2013 Jun; 4(3):95-105. PubMed ID: 23730503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
    Lamine F; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2016; 146():w14282. PubMed ID: 26922155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of oral glucose-lowering agents in patients with renal impairment].
    Scheen AJ
    Rev Med Suisse; 2012 Aug; 8(351):1614-20. PubMed ID: 22988715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
    Awal HB; Nandula SR; Domingues CC; Dore FJ; Kundu N; Brichacek B; Fakhri M; Elzarki A; Ahmadi N; Safai S; Fosso M; Amdur RL; Sen S
    Cardiovasc Diabetol; 2020 Jun; 19(1):72. PubMed ID: 32493344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
    Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
    Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T; Davies GI; Rice S; Chess J; Stephens JW
    Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
    Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
    Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines.
    Weinrauch LA; Segal AR; Bayliss GP; Liu J; Wisniewski E; D'Elia JA
    Clin Kidney J; 2017 Oct; 10(5):661-665. PubMed ID: 28979777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
    McKeage K
    Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.